Answers are grounded in this paper and cite their sources.
In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor activity and manageable toxicity in patients with advanced solid tumors. Results from transcriptome-based analysis enhanced our understanding of the genomic landscape of FGFR fusion-driven tumors, informing clinical trial design and generating hypotheses for resistance mechanisms. See related article by Grivas et al., p. 4572.
No takes yet. Share an insight, caveat, or question.
Chehade et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: